AI Summary In a phase 3 placebo-controlled trial, terlipressin plus albumin reversed hepatorenal syndrome more often than placebo plus albumin.
Medically reviewed.
Terlivaz (terlipressin) is a vasoconstrictor medication used to treat hepatorenal syndrome (HRS) in people with advanced liver disease. It is given through a vein by healthcare professionals, usually together with albumin. Terlivaz narrows blood vessels in the abdomen, which helps restore blood flow to the kidneys and supports kidney recovery. It is an FDA-approved treatment for HRS. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Terlivaz's role in HRS care — how it works, who may be eligible, what treatment involves, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT TERLIVAZ TREATMENT
Terlipressin is a prescription medicine sold under the brand name Terlivaz. It belongs to a group of medications called vasoconstrictors, which narrow blood vessels. Terlivaz is used to treat hepatorenal syndrome (HRS), a serious loss of kidney function that can develop in people with advanced liver disease.
In HRS, cirrhosis widens blood vessels in the abdomen. Less blood reaches the kidneys, and they stop working as they should. Terlivaz narrows the blood vessels in the abdomen, increases effective blood volume, and sends more blood to the kidneys. It is an FDA-approved treatment for HRS.
Terlivaz is given through a vein (intravenously) by healthcare professionals, and it is commonly used with albumin infusion. Other medications in the same group include midodrine and octreotide.
WHO TERLIVAZ MAY BE SUITABLE FOR
Eligibility for Terlivaz depends on your diagnosis, your kidney function, and your overall health. Your healthcare provider may prescribe it if you have hepatorenal syndrome, if your kidney function is getting worse because of cirrhosis, or if you need vasoconstrictor therapy together with albumin. Most people who receive it are in the hospital for complications of advanced liver disease.
Before HRS is diagnosed, your care team looks for other causes of kidney injury, such as low fluid volume or medications that harm the kidneys. Your medical history, current health status, liver condition, and other medications all factor into whether Terlivaz is an appropriate option for you.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should receive Terlivaz. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver and kidney health.
ELIGIBILITY OVERVIEW
Terlivaz may be considered for adults with the following conditions or treatment needs:
Before recommending Terlivaz, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW TERLIVAZ CAN HELP YOUR KIDNEYS
In advanced cirrhosis, blood vessels in the abdomen widen. Effective blood volume drops, and less blood reaches the kidneys. This reduced blood flow is what causes hepatorenal syndrome.
Terlivaz is a vasopressin analog. It constricts (narrows) blood vessels in the abdominal circulation, which increases effective blood volume and blood pressure. More blood is then redirected to the kidneys, which supports kidney function recovery.
For people with HRS, these effects can support treatment goals such as reversing HRS and improving kidney function. In clinical trials, Terlivaz reversed HRS in about 40% of treated patients. Terlivaz is not used on its own — providers pair it with albumin and closely monitor kidney function, blood pressure, and oxygen levels throughout treatment.
LIVER BENEFITS
In advanced cirrhosis, blood vessels in the abdomen widen, and circulation falls out of balance. Terlivaz is a vasoconstrictor, so it narrows the blood vessels in the abdominal circulation. This helps restore circulatory balance, which is one of the main problems your care team works to correct.
When abdominal vessels widen, less blood is available to the rest of the body. This is called low effective blood volume. By narrowing those vessels, Terlivaz increases effective blood volume, so your circulation can be steadier while your liver disease is managed.
Your kidneys are the organs most at risk when advanced liver disease disrupts circulation. Terlivaz improves blood flow to the kidneys. Better flow gives them a chance to recover, which supports the hepatorenal syndrome treatment goals of reversing the syndrome and improving kidney function.
Terlivaz is commonly given with albumin infusion, which also supports blood volume and circulation. Your care team uses both as part of one hospital plan. They follow your kidney function, blood pressure, and oxygen levels, and they adjust your care as you respond.
Terlivaz supports your liver care by easing the circulation problems that lead to kidney injury in advanced liver disease. It should only be given and monitored by a qualified healthcare team, usually in the hospital.
TREATMENT PROCESS
Terlivaz is supplied as an injection that goes into a vein (intravenous, or IV). You do not prepare it yourself. Your hospital care team handles all preparation.
Your healthcare provider sets your dose. If your kidneys have not responded well after about 3 days, your provider may raise the dose, based on your response and how well you tolerate it.
Terlivaz is given through a vein by healthcare professionals, usually in the hospital. It is not a pill, and it is not something you give yourself at home. It is commonly given together with albumin infusion.
Treatment is usually short-term. It continues for up to 14 days, or until kidney function improves, side effects occur, or the therapy is no longer helping. Your care team typically checks your response within the first few days.
Your hospital pharmacy stores Terlivaz according to the manufacturer's recommendations.
Your care team closely monitors kidney function, oxygen levels, blood pressure, and treatment response. Tell your nurse or doctor right away if you have trouble breathing, belly pain, or any other new symptom.
BENEFITS AND SAFETY
Terlivaz (terlipressin) may support people with hepatorenal syndrome by improving blood flow to the kidneys and helping restore circulatory balance. It is an FDA-approved treatment for HRS and is commonly used with albumin infusion. The extent of benefit varies from person to person, depending on liver condition, kidney function, and how the body responds to therapy. Terlivaz is not a stand-alone solution — it is given as part of hospital care with close monitoring of kidney function, blood pressure, and oxygen levels.
As with any medication, Terlivaz may cause side effects, including abdominal pain, nausea, shortness of breath, high blood pressure, and reduced blood flow to the hands and feet (peripheral ischemia). Your care team monitors you throughout treatment and assesses whether Terlivaz remains a suitable option for you.
BENEFITS
The main goal of Terlivaz is to improve kidney function, which is the organ most at risk in hepatorenal syndrome. For you, that means a treatment aimed at the problem that is affecting your kidneys. Your care team uses kidney and blood tests to judge whether it is working, and they share what the results mean for your care.
Terlivaz is an FDA-approved treatment for hepatorenal syndrome. It gives eligible patients an option designed for this serious complication of advanced liver disease, after other causes of kidney injury have been considered. In clinical trials, it reversed HRS in about 40% of treated patients. Treatment is usually short-term, and results differ from person to person.
By improving effective blood volume, Terlivaz helps steady circulation in people with advanced liver disease. During your hospital stay, your care team checks your blood pressure and oxygen levels closely, so changes can be noticed early and your treatment can be adjusted if needed.
Terlivaz is commonly used with albumin infusion. Albumin helps expand blood volume and supports blood flow to the kidneys, so the two treatments work toward the same goal. Your care team decides how to combine them and how long to continue, based on how you respond.
Your care team monitors your breathing, oxygen levels, and blood pressure throughout treatment. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support to help ensure safe use.
SUPPORTING YOUR RECOVERY
Most people receive Terlivaz in the hospital. After your condition is stable, long-term care focuses on protecting your liver and kidneys.
These habits can support your recovery and your long-term liver health. Your hepatology team will tailor them to your needs.
Areas that may support recovery:
common questions
Terlivaz may be an option for people with hepatorenal syndrome (HRS), worsening kidney function related to cirrhosis, or a need for vasoconstrictor therapy alongside albumin. Most are in the hospital for complications of advanced liver disease. Before starting, your care team reviews your kidney function, blood pressure, oxygen levels, current medications, and test results, and looks for other causes of kidney injury. Talk with your healthcare professional about whether Terlivaz fits your situation.
Terlivaz reversed hepatorenal syndrome in about 40% of treated patients in clinical trials. It is an FDA-approved treatment that improves blood flow to the kidneys, but it does not cure the advanced liver disease behind HRS. Results vary with liver condition, kidney function, and how your body responds. Your care team checks your response within the first few days. Ask your healthcare professional what outcome to expect in your own case.
No. Healthcare professionals give Terlivaz through a vein, and most people receive it in the hospital. You do not prepare or give it yourself. In the hospital, your care team can closely monitor your kidney function, oxygen levels, blood pressure, and response to treatment. If you have questions about where and how Terlivaz would be given, ask your healthcare professional before treatment begins.
Terlivaz treatment is usually short-term and continues for up to 14 days. It may stop sooner if your kidney function improves, side effects occur, or the therapy is no longer helping. Your care team typically checks your response within the first few days and adjusts the plan based on how you respond and tolerate treatment. Your healthcare professional can explain what to expect for your own treatment plan.
Common side effects include abdominal pain, nausea, shortness of breath, high blood pressure, and peripheral ischemia, which means reduced blood flow to the hands and feet. Your care team monitors your breathing, oxygen levels, and blood pressure throughout treatment. Tell your nurse or doctor right away if you have trouble breathing, belly pain, or any other new symptom. Discuss the potential benefits and risks of Terlivaz with your healthcare professional before treatment.
Yes. Terlivaz is commonly used with albumin infusion. Albumin helps expand blood volume and supports kidney blood flow, so the two treatments work toward the same goal of improving circulation to the kidneys. Terlivaz is not used on its own. Your care team decides how to combine them and how long to continue, based on your response, so ask your healthcare professional about your full treatment plan.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
